Business Context and Reporting Period
CareCloud, Inc. (CCLD) is a healthcare information technology company providing technology-enabled revenue cycle management (RCM), cloud-based software, and medical practice management services. This summary covers the quarterly period ended September 30, 2025 (Q3 2025) and the nine months ended September 30, 2025 (YTD 2025), compared to the same periods in 2024.
Key Financial Metrics
| Metric | Q3 2025 | Q3 2024 | YTD 2025 | YTD 2024 |
|---|---|---|---|---|
| Net Revenue | $31.1 million | $28.5 million | $86.1 million | $82.6 million |
| Operating Income | $3.2 million | $3.3 million | $8.2 million | $5.7 million |
| Net Income | $3.1 million | $3.1 million | $7.9 million | $4.6 million |
| Net Income Attributable to Common Shareholders | $1.7 million | ($0.7 million) | $2.4 million | ($4.5 million) |
| Adjusted EBITDA | $7.7 million | $6.8 million | $19.9 million | $16.9 million |
| Cash and Restricted Cash | $5.1 million | $2.8 million | $5.1 million | $2.8 million |
| Debt (Line of Credit) | $6.5 million | $0 | $6.5 million | $0 |
| Working Capital | $6.1 million | $5.2 million | $6.1 million | $5.2 million |
Material Changes vs. Prior Period
- Revenue Growth: Net revenue increased 9% in Q3 and 4% YTD, driven primarily by technology-enabled business solutions ($21.6M in Q3) and the inclusion of revenue from the Medsphere acquisition ($3.4M in Q3).
- Profitability: While GAAP Net Income remained flat in Q3, Net Income attributable to common shareholders improved significantly due to the conversion of Series A Preferred Stock in March 2025, which reduced the preferred dividend burden.
- Expense Trends:
- R&D: Increased 98% in Q3 and 39% YTD due to a shift in development activities where fewer costs qualified for capitalization.
- Selling & Marketing: Decreased 18% in Q3 and 30% YTD due to headcount reductions.
- Amortization: Increased 23% in Q3 due to Medsphere intangible assets but decreased 5% YTD as older assets became fully amortized.
- Acquisitions: The company acquired Medsphere Systems Corporation (August 2025) and RevNu Medical Management (April 2025), adding $11.2 million in goodwill and expanding its inpatient and audiology footprints.
Guidance, Outlook, and Risks
- Liquidity: Management expects sufficient liquidity to meet obligations for the next 12 months. The company terminated its line of credit with Silicon Valley Bank in August 2025 and secured a new $10 million revolving line of credit with Provident Bank in September 2025.
- Dividends: Preferred stock dividends, suspended in December 2023, resumed in February 2025. As of September 30, 2025, approximately $6.9 million in dividends remain undeclared/accumulated.
- Key Risks:
- Integration: Risks associated with integrating Medsphere and RevNu, including legal exposure and operational synergies.
- Offshore Operations: Reliance on cost-efficient operations in Pakistan and Sri Lanka, which face regulatory and political uncertainties.
- Competition & Technology: Need to keep pace with AI development and cybersecurity threats while competing with larger entities.
- Debt Covenants: Compliance with covenants under the new Provident Bank credit agreement.
Investor Verification Checklist
- Preferred Stock Dividends: Verify the status of the ~$6.9 million in accumulated but undeclared preferred dividends and the impact on future cash flow.
- Acquisition Integration: Monitor the realization of synergies and revenue retention from the Medsphere and RevNu acquisitions.
- Debt Structure: Confirm compliance with the new Provident Bank credit facility covenants and the utilization of the $10 million line.
- R&D Capitalization: Assess the sustainability of the increased R&D expense ratio and the criteria for capitalizing software development costs.
- Offshore Exposure: Review the stability of operations in Pakistan and Sri Lanka, which account for a significant portion of personnel costs.